Medical Market Report

Global Non-Insulin Therapies for Diabetes Market By Type (Alpha-glucosidase Inhibitors, Amylin Agonists, Biguanides, Dipeptidyl Peptidase-4 (DPP4) Inhibitors, Glinides / Meglitinides, GLP-1 Analogs / GLP-1 Agonists, Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors, Sulfonylureas, and Thiazolidinediones), By Application (Hospital Pharmacy, Retail Pharmacies, and Online Pharmacy), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2020-2029

  • 139320
  • 18-Dec
  • PDF/PPT/Word
  • ★ ★ ★ ★ ★
    ★ ★ ★ ★ ★
  • Report Details

    Global Non-Insulin Therapies for Diabetes Market is estimated to be valued US$ XX.X million in 2019. The report on Non-Insulin Therapies for Diabetes Market provides qualitative as well as quantitative analysis in terms of market dynamics, competition scenarios, opportunity analysis, market growth, etc. for the forecast year up to 2029. The global non-insulin therapies for diabetes market is segmented on the basis of Type, Application, and geography.

    Europe market was valued at US$ XX.X million in 2018 and is projected to reach US$ XX.X million in 2029, and register a CAGR of X.X% during the forecast period, according to a new Market.us (Prudour Research) study.

    Non-Insulin Therapies for Diabetes Market Scope:

    By type, the market is segmented into Alpha-glucosidase Inhibitors, Amylin Agonists, Biguanides, Dipeptidyl Peptidase-4 (DPP4) Inhibitors, Glinides / Meglitinides, GLP-1 Analogs / GLP-1 Agonists, Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors, Sulfonylureas, and Thiazolidinediones. By Application, the market is divided into Hospital Pharmacy, Retail Pharmacies, and Online Pharmacy.
    Based on geography, the market is analyzed across North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa. Major players profiled in the report include GSK, Eli Lilly, Sumitomo Dainippon Pharma, Intarcia Therapeutics, Servier, Jiangsu Hansoh Pharmaceutical, Novo Nordisk, Emisphere, Uni-Bio Science Group, Takeda, 3SBio, Merck, Dong-A Pharmaceutical, Luye Pharma Group, Eurofarma, Geropharm, Alkem Labs, SatRx, Pfizer, and Jiangsu Hengrui Medicine.

    Key Market Segments

    Type

    Alpha-glucosidase Inhibitors

    Amylin Agonists

    Biguanides

    Dipeptidyl Peptidase-4 (DPP4) Inhibitors

    Glinides / Meglitinides

    GLP-1 Analogs / GLP-1 Agonists

    Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors

    Sulfonylureas

    Thiazolidinediones

    Application

    Hospital Pharmacy

    Retail Pharmacies

    Online Pharmacy

    Key Market Players included in the report:

    GSK

    Eli Lilly

    Sumitomo Dainippon Pharma

    Intarcia Therapeutics

    Servier

    Jiangsu Hansoh Pharmaceutical

    Novo Nordisk

    Emisphere

    Uni-Bio Science Group

    Takeda

    3SBio

    Merck

    Dong-A Pharmaceutical

    Luye Pharma Group

    Eurofarma

    Geropharm

    Alkem Labs

    SatRx

    Pfizer

    Jiangsu Hengrui Medicine

    Reasons to Get this Report:

    In an insight outlook, this research report has dedicated to several quantities of analysis – industry research (global industry trends) and Non-Insulin Therapies for Diabetes Market share analysis of high players, along with company profiles, and which collectively include about the fundamental opinions regarding the market landscape; emerging and high-growth sections of Non-Insulin Therapies for Diabetes Market; high-growth regions; and market drivers, restraints, and also market chances.
    The analysis covers Non-Insulin Therapies for Diabetes Market and its advancements across different industry verticals as well as regions. It targets estimating the current market size and growth potential of the global Non-Insulin Therapies for Diabetes Market across sections such as also Application and representatives.
    Additionally, the analysis also has a comprehensive review of the crucial players on the Non-Insulin Therapies for Diabetes Market together side their company profiles, SWOT analysis, latest advancements, and business plans.

    The analysis objectives of the report are:

    To equitably share in-depth info regarding the crucial elements impacting the increase of industry (growth capacity, chances, drivers, and industry-specific challenges and risks).
    To know the Non-Insulin Therapies for Diabetes Market by pinpointing its many subsegments.
    To profile the important players and analyze their growth plans.
    To endeavor the amount and value of Non-Insulin Therapies for Diabetes sub-markets, depending on key regions (various vital states).
    To analyze Non-Insulin Therapies for Diabetes Market concerning growth trends, prospects, and also their participation in the entire sector.
    To examine and study the Non-Insulin Therapies for Diabetes Market size (volume & value) from the company, essential regions/countries, products, and Application, background information from 2013 to 2018, and also prediction to 2029.
    Primary worldwide Non-Insulin Therapies for Diabetes Market manufacturing companies, to specify, clarify and analyze the product sales amount, value and market share, market rivalry landscape, SWOT analysis and development plans next coming years.
    To examine competitive progress such as expansions, arrangements, new product launches, and acquisitions on the market.

  • Table Of Content 
    1. Non-Insulin Therapies for Diabetes Market Introduction
    

    1.1. Definition
    
1.2. Taxonomy
    
1.3. Research Scope
    

    2. Executive Summary
    

      2.1. Key Findings by Major Segments
    
  2.2. Top strategies by Major Players
    

    3. Global Non-Insulin Therapies for Diabetes Market Overview
    

    3.1. Non-Insulin Therapies for Diabetes Market Dynamics
    

        3.1.1. Drivers
    
    3.1.2. Opportunities
    
    3.1.3. Restraints
    
    3.1.4. Challenges
    

      3.2. PESTLE Analysis
    
  3.3. Opportunity Map Analysis
    
  3.4. PORTER’S Five Forces Analysis
    
  3.5. Market Competition Scenario Analysis
    
  3.6. Product Life Cycle Analysis
    
  3.7. Opportunity Orbits
    
  3.8. Production Analysis by Region/Company
    
  3.9. Industry chain Analysis
    
  3.10. Marketing Strategy
    

    4. Global Non-Insulin Therapies for Diabetes Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
    

      4.1. Global Non-Insulin Therapies for Diabetes Market Analysis by Type: Introduction
    
  4.2. Market Size and Forecast by Region
    
  4.3. Alpha-glucosidase Inhibitors
    

      4.4. Amylin Agonists
    

      4.5. Biguanides
    

      4.6. Dipeptidyl Peptidase-4 (DPP4) Inhibitors
    

      4.7. Glinides / Meglitinides
    

      4.8. GLP-1 Analogs / GLP-1 Agonists
    

      4.9. Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors
    

      4.10. Sulfonylureas
    

      4.11. Thiazolidinediones
    

    5. Global Non-Insulin Therapies for Diabetes Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
    

      5.1. Global Non-Insulin Therapies for Diabetes Market Analysis by Application: Introduction
    
  5.2. Market Size and Forecast by Region
    
  5.3. Hospital Pharmacy
    

      5.4. Retail Pharmacies
    

      5.5. Online Pharmacy
    

    6. Global Non-Insulin Therapies for Diabetes Market Value & Volume ((US$ Mn & ‘000 Units)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
    

      6.1. North America
    

        6.1.1. North America Non-Insulin Therapies for Diabetes Market: Regional Trend Analysis
    

         6.1.1.1. US
    
     6.1.1.2. Canada
    
     6.1.1.3. Mexico
    

      6.2.1. Europe
    

        6.2.1. Europe Non-Insulin Therapies for Diabetes Market: Regional Trend Analysis
    

         6.2.1.1. Germany
    
     6.2.1.2. France
    
     6.2.1.3. UK
    
     6.2.1.4. Russia
    
     6.2.1.5. Italy
    
     6.2.1.6. Spain
    
     6.2.1.7. Rest of Europe
    

      6.3. Asia-Pacific
    

        6.3.1. Asia-Pacific Non-Insulin Therapies for Diabetes Market: Regional Trend Analysis
    

         6.3.1.1. China
    
     6.3.1.2. Japan
    
     6.3.1.3. Korea
    
     6.3.1.4. India
    
     6.3.1.5. Rest of Asia-Pacific
    

      6.4. Latin America
    

        6.4.1. Latin America Non-Insulin Therapies for Diabetes Market: Regional Trend Analysis
    

         6.4.1.1. Brazil
    
     6.4.1.2. Argentina
    
     6.4.1.3. Rest of Latin America
    

      6.5. Middle East and Africa
    

        6.5.1. Middle East and Africa Non-Insulin Therapies for Diabetes Market: Regional Trend Analysis
    

         6.5.1.1. GCC
    
     6.5.1.2. South Africa
    
     6.5.1.3. Israel
    
     6.5.1.4. Rest of MEA
    

    7. Global Non-Insulin Therapies for Diabetes Market Competitive Landscape, Market Share Analysis, and Company Profiles
    

      7.1. Market Share Analysis
    
  7.2. Company Profiles
    
  7.3. GSK
    

        7.3.1. Company Overview
    
    7.3.2. Financial Highlights
    
    7.3.3. Product Portfolio
    
    7.3.4. SWOT Analysis
    
    7.3.5. Key Strategies and Developments
    

      7.4. Eli Lilly
    

        7.4.1. Company Overview
    
    7.4.2. Financial Highlights
    
    7.4.3. Product Portfolio
    
    7.4.4. SWOT Analysis
    
    7.4.5. Key Strategies and Developments
    

      7.5. Sumitomo Dainippon Pharma
    

        7.5.1. Company Overview
    
    7.5.2. Financial Highlights
    
    7.5.3. Product Portfolio
    
    7.5.4. SWOT Analysis
    
    7.5.5. Key Strategies and Developments
    

      7.6. Intarcia Therapeutics
    

        7.6.1. Company Overview
    
    7.6.2. Financial Highlights
    
    7.6.3. Product Portfolio
    
    7.6.4. SWOT Analysis
    
    7.6.5. Key Strategies and Developments
    

      7.7. Servier
    

        7.7.1. Company Overview
    
    7.7.2. Financial Highlights
    
    7.7.3. Product Portfolio
    
    7.7.4. SWOT Analysis
    
    7.7.5. Key Strategies and Developments
    

      7.8. Jiangsu Hansoh Pharmaceutical
    

        7.8.1. Company Overview
    
    7.8.2. Financial Highlights
    
    7.8.3. Product Portfolio
    
    7.8.4. SWOT Analysis
    
    7.8.5. Key Strategies and Developments
    

      7.9. Novo Nordisk
    

        7.9.1. Company Overview
    
    7.9.2. Financial Highlights
    
    7.9.3. Product Portfolio
    
    7.9.4. SWOT Analysis
    
    7.9.5. Key Strategies and Developments
    

      7.10. Emisphere
    

        7.10.1. Company Overview
    
    7.10.2. Financial Highlights
    
    7.10.3. Product Portfolio
    
    7.10.4. SWOT Analysis
    
    7.10.5. Key Strategies and Developments
    

      7.11. Uni-Bio Science Group
    

        7.11.1. Company Overview
    
    7.11.2. Financial Highlights
    
    7.11.3. Product Portfolio
    
    7.11.4. SWOT Analysis
    
    7.11.5. Key Strategies and Developments
    

      7.12. Takeda
    

        7.12.1. Company Overview
    
    7.12.2. Financial Highlights
    
    7.12.3. Product Portfolio
    
    7.12.4. SWOT Analysis
    
    7.12.5. Key Strategies and Developments
    

      7.13. 3SBio
    

        7.13.1. Company Overview
    
    7.13.2. Financial Highlights
    
    7.13.3. Product Portfolio
    
    7.13.4. SWOT Analysis
    
    7.13.5. Key Strategies and Developments
    

      7.14. Merck
    

        7.14.1. Company Overview
    
    7.14.2. Financial Highlights
    
    7.14.3. Product Portfolio
    
    7.14.4. SWOT Analysis
    
    7.14.5. Key Strategies and Developments
    

      7.15. Dong-A Pharmaceutical
    

        7.15.1. Company Overview
    
    7.15.2. Financial Highlights
    
    7.15.3. Product Portfolio
    
    7.15.4. SWOT Analysis
    
    7.15.5. Key Strategies and Developments
    

      7.16. Luye Pharma Group
    

        7.16.1. Company Overview
    
    7.16.2. Financial Highlights
    
    7.16.3. Product Portfolio
    
    7.16.4. SWOT Analysis
    
    7.16.5. Key Strategies and Developments
    

      7.17. Eurofarma
    

        7.17.1. Company Overview
    
    7.17.2. Financial Highlights
    
    7.17.3. Product Portfolio
    
    7.17.4. SWOT Analysis
    
    7.17.5. Key Strategies and Developments
    

      7.18. Geropharm
    

        7.18.1. Company Overview
    
    7.18.2. Financial Highlights
    
    7.18.3. Product Portfolio
    
    7.18.4. SWOT Analysis
    
    7.18.5. Key Strategies and Developments
    

      7.19. Alkem Labs
    

        7.19.1. Company Overview
    
    7.19.2. Financial Highlights
    
    7.19.3. Product Portfolio
    
    7.19.4. SWOT Analysis
    
    7.19.5. Key Strategies and Developments
    

      7.20. SatRx
    

        7.20.1. Company Overview
    
    7.20.2. Financial Highlights
    
    7.20.3. Product Portfolio
    
    7.20.4. SWOT Analysis
    
    7.20.5. Key Strategies and Developments
    

      7.21. Pfizer
    

        7.21.1. Company Overview
    
    7.21.2. Financial Highlights
    
    7.21.3. Product Portfolio
    
    7.21.4. SWOT Analysis
    
    7.21.5. Key Strategies and Developments
    

      7.22. Jiangsu Hengrui Medicine
    

        7.22.1. Company Overview
    
    7.22.2. Financial Highlights
    
    7.22.3. Product Portfolio
    
    7.22.4. SWOT Analysis
    
    7.22.5. Key Strategies and Developments
    

    8. Assumptions and Acronyms
    
9. Research Methodology
    
10. Contact
  • Inquiry Before Buying

    Inquiry Form

  • Request Sample

    Request for Sample

Related Reports

Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.